Transgene

Transgene Gross Margin

The Gross Margin of Transgene (TNG.PA) as of Oct 9, 2026 is -219.36 %. In the previous year, Gross Margin was -91.92 % — a change of 138.63% (lower).

Gross Margin

-219.36 %

YoY

138.63%

Last updated:

Gross Margin of Transgene is 2022 -219.36 % . Gross Margin of Transgene was 2021 -91.92 % . It decreases by 138.63% lower compared to the previous year.

Transgene's gross margin stands at -219.4%, down from -190.2% several years earlier.

The Transgene Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2020
-190.20 EUR
Jan 1, 2021
-91.92 EUR
Jan 1, 2022
-219.36 EUR
The Transgene Gross Margin history
YEARGross MarginYoY
-219.36 %+138.63%
-91.92 %-51.67%
-190.20 %—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Gross Margin of Transgene is -219.36 % in 2022.

Gross Margin of Transgene changed from -91.92 % to -219.36 %, representing a 138.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Transgene since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Transgene

All Key Metrics — Transgene